(Q36765820)

16 August 2017

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer (English)

1 reference

16 August 2017

A J Zurita

1

1 reference

16 August 2017

L L Pisters

2

1 reference

16 August 2017

X Wang

3

1 reference

16 August 2017

P Troncoso

4

1 reference

16 August 2017

P Dieringer

5

1 reference

16 August 2017

J F Ward

6

1 reference

16 August 2017

J W Davis

7

1 reference

16 August 2017

C A Pettaway

8

1 reference

16 August 2017

C J Logothetis

9

1 reference

16 August 2017

L C Pagliaro

10

1 reference

16 August 2017

26 May 2015

1 reference

Prostate Cancer and Prostatic Diseases

16 August 2017

1 reference

16 August 2017

18

1 reference

16 August 2017

3

1 reference

16 August 2017

276-280

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2015.23

16 August 2017

0 references

cites work

Platinum-based chemotherapy for variant castrate-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Surgical management of lymph-node-positive prostate cancer: improves symptomatic control

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

The Clavien-Dindo classification of surgical complications: five-year experience.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a r

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821010

Prognostic factors in lymph node-positive prostate cancer

5 September 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2015.23

Risk of prostate carcinoma death in patients with lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2015.23

Cancer volume of lymph node metastasis predicts progression in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2015.23

Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N+ Patients Treated with Radical Prostatecto

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2015.23

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2015.23

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2015.23

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2015.23

31 March 2020

Identifiers

DOI

10.1038/PCAN.2015.23

1 reference

16 August 2017

1 reference

16 August 2017

1 reference